The Ets transcription factor PU.1, encoded by the gene Sfpi1, functions in a concentration-dependent manner to promote myeloid and B-cell development and has been implicated in myeloid and lymphoid leukemias. To determine the consequences of reducing PU.1 concentration during hematopoiesis, we analyzed mice with two distinct hypomorphic alleles of Sfpi1 that produce PU.1 at B20% (BN) or B2% (Blac) of wild-type levels. Myeloid development was impaired in these mice, but less severely than in Sfpi1 null mice. To identify the downstream target genes that respond to changes in PU.1 concentration, we analyzed ex vivo interleukin-3 dependent myeloid cell lines established from Sfpi1
Introduction
Transcription factors regulate hematopoiesis by activating or repressing lineage-specific genes involved in cell fate decisions and lineage commitment. PU.1, encoded by the gene Sfpi1 in mice and Spi-1 in humans, belongs to the Ets transcription factor family. 1 Over 100 target genes of PU.1 have been identified in myeloid and B cells. Knockout of Sfpi1 results in fetal or perinatal lethality, absence of myeloid and B cells and abnormal T-cell and natural killer (NK)-cell development. [2] [3] [4] [5] Mutations that inactivate PU.1 are associated with acute myeloid leukemia (AML) in humans and are sufficient to cause AML in mouse models. [6] [7] [8] [9] [10] [11] Altered PU.1 levels also cause T-cell leukemias in mice. 11, 12 Early on, PU.1 was recognized to be expressed at significantly higher concentrations in macrophages than B cells. 13 High PU.1 levels are required to generate macrophages both in vitro and in vivo. [14] [15] [16] Low concentrations are required for terminal differentiation of B cells, and forced expression results in a block to B-cell development. 16 PU.1 was also shown to regulate macrophage/neutrophil cell fate decisions. 17 Cells expressing low levels of PU.1 had a mixed expression pattern, whereas cells expressing high levels favored macrophage development by activating and repressing distinct subsets of genes. 18 These studies demonstrate that PU.1 functions as a concentrationdependent cell fate determinant.
PU.1 is expressed at uniform levels in hematopoietic stem cells and common myeloid and lymphoid progenitors. 19, 20 PU.1 increases during myeloid terminal differentiation and decreases during B-cell terminal differentiation. 19, 20 Levels also decrease after erythroid, T-cell or NK-cell commitment, and forced expression of PU.1 results in a block to erythroid and T-cell development. [19] [20] [21] [22] PU.1 is critical in myeloid/erythroid fate decisions and interacts with the transcription factor GATA-1. [23] [24] [25] PU.1 binds to GATA-1 on erythroid target genes, recruits repressive chromatin modification factors and promotes myelopoiesis at the expense of erythropoiesis. [24] [25] [26] In contrast, it is unknown how T/NK-cell genes respond to changes in PU.1 concentration or why PU.1 must be downregulated for terminal differentiation.
Our laboratory recently generated a hypomorphic allele of Sfpi1 termed BN 15 that results in failure of B-cell development, abnormal T-cell development, and hyperproliferation of immature myeloid cells. Analysis of Sfpi1 BN/BN cultured cells revealed that they express B20% of wild-type PU.1 protein levels. This allele is unique because it results in a reduction of PU.1 levels in all cell types. 15 This is in contrast to a hypomorphic allele created by deletion of the upstream regulatory enhancer at À14 kb, which knocks down PU.1 in most hematopoietic cell types but results in increased PU.1 levels in T cells. 8, 12 In this study, we generated a second distinct hypomorphic allele of Sfpi1, termed Blac, to determine the concentrationdependent effects of PU.1 on target genes and lineage decisions.
Analysis of Sfpi1
Blac/Blac fetal liver cells cultured in interleukin-3 (IL-3) suggests that they express B2% of wild-type PU.1 protein levels. These cells fail to terminally differentiate as a consequence of low PU.1 expression and can be maintained as cell lines. To determine gene regulation in response to varied PU.1 concentrations, we compared gene expression in Sfpi1 BN/BN and Sfpi1
Blac/Blac cells to Sfpi1 -/-cells. With this unique allelic system, we can study the effects of three discrete concentrations of PU.1 at B20, B2 and 0% of wild-type levels. Our results show that PU.1 both activates and represses distinct groups of genes. Genes activated in a gradient fashion included a cluster of myeloid-specific direct PU.1 target genes, while genes repressed in a gradient fashion included clusters of erythroidspecific and, unexpectedly, T-cell-and NK-cell-specific genes.
T/NK-cell genes were also repressed in a dose-dependent manner in IL-7 dependent pro-B cells. In conclusion, our results suggest that PU.1 functions in a concentration-dependent manner to promote myeloid or B-cell differentiation and concurrently repress T-cell and NK-cell development.
Materials and methods

Gene targeting of mice and cell culture Sfpi1
BN/BN mice were generated as previously described.
15
Sfpi1
Blac/Blac mice were generated by Cre-mediated excision of the neomycin gene by mating Sfpi1 þ /BN mice to EIIA-Cre mice (Jackson Laboratories). F1 mice lacking PGK-NEO were crossed to Black/Swiss mice (Jackson Laboratories) to remove the Cre transgene. Offspring lacking both PGK-NEO and the Cre transgene were termed Sfpi1 þ /Blac . Excision was verified by PCR and by DNA-sequencing of PCR-amplified genomic DNA. Genotyping was performed with primers outlined in Houston et al. 15 Primers used to verify loss of Cre transgene are as follows:
, and Cre4 (5 0 -GTGAAACAGCA TTGCTGTCACTT-3 0 ). Timed matings were performed as described. 15 Colony-forming unit (CFU) assays were performed using day 14.5 fetal liver cells as previously described. 27 IL-3 dependent cell lines were generated by culturing day 14.5 fetal liver cells in complete Iscove's modified Dulbecco medium (IMDM) with IL-3 (5 ng ml À1 ), IL-6 (10 ng ml À1 ) and SCF (100 ng ml À1 ; Peprotech, Rocky Hill, NJ, USA) for 4 days, followed by passage every 4 days in complete IMDM containing 5 ng ml À1 IL-3. Generation of pro-B cell lines has been described. 27 For cytokine switching experiments, cells were washed twice in complete IMDM and replated in triplicate in complete IMDM with IL-3 (5 ng ml À1 ) or GM-CSF (0.5 ng ml À1 ; Peprotech).
Flow cytometry and immunoblot
Flow cytometric analysis was performed on cells stained with the biotin-conjugated antibodies 15.3.2 (IgE), RB6-8C5 (Gr-1), 2.4G2 (FcgRII/III), 1D3 (CD19), RA3-6B2 (B220) or phycoerythrin-conjugated antibody 2B8 (c-Kit). Biotin-conjugated antibodies were visualized by secondary staining with streptavidin-allophycocyanin conjugate (BD Pharmingen, San Diego, CA, USA). Immunoblotting was performed with rabbit anti-PU.1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and HRP-conjugated anti-rabbit secondary antibody (Pierce, Rockford, IL, USA), as previously described. 28 
RT-PCR analysis
Reverse transcription (RT)-PCR and real-time RT-PCR with a Cepheid SmartCycler were performed as previously described. 28, 29 Real-time RT-PCR quantitation was based on normalization to G6pdh. Primers are listed in Supplementary  Table S1 .
Affymetrix GeneChips
Two separate IL-3 dependent cell lines (n ¼ 2) were established for each homozygous genotype. RNA was isolated from at least 6 Â 10 7 cells in each IL-3 dependent cell line (once for line n 1 , line n 2 in duplicate, total triplicate analysis) with RNA-Bee (Tel-Test Inc., Friendswood, TX, USA) and purified with RNeasy (Qiagen, Valencia, CA, USA). The RNA was labeled with the Ovation Biotin System protocol (NuGEN, San Carlos, CA, USA), hybridized to Affymetrix Mouse Genome Microarray 430 2.0 and analyzed as described previously. 30 Data (Supplementary  Table S2 ) was analyzed with GeneSpring software (Agilent Technologies, Santa Clara, CA, USA) and normalized per chip to the 50th percentile and per gene to the median, with measurements less than 0.01 set to 0.01. Additionally, all samples were normalized relative to expression in Sfpi1 À/À cells. We used the program Database for Annotation, Visualization and Integrated Discovery (DAVID) for gene functional classification. 31 
Bioinformatic analysis
We assembled a database of known direct PU.1 target genes (Supplementary Table S3 ). A total of 99 biochemically characterized PU.1 binding site sequences from 93 validated PU.1 target genes were identified from the primary literature. These included the known core PU.1 binding site GGAA or AGAA and five flanking nucleotides on either side. 32 Based on these sequences, a position weight matrix (PWM) was generated to identify consensus PU.1 sites and putative targets. A standard PU.1 matrix was also obtained from the TRANSFAC database. 33 A list of housekeeping genes was assembled as a negative control for PU.1 regulation by finding genes with the ontology 'cell growth and/or maintenance' that had similar expression values (o3% difference) between all samples. To identify putative PU.1 binding sites in promoters of activated, repressed or housekeeping genes, we searched the conserved upstream 1 kb regions identified based on the transcriptional start sites annotated in the NCBI RefSeq database. The 17-species multiple alignment files for each of these upstream 1 kb sequences was downloaded from the UCSC Golden Path database (http:// genome.ucsc.edu). 34 Tffind, a computer program written in C, was used to locate patterns of PU.1 sites within the multiple alignment files for each gene promoter. Tffind identifies matches to PWMs in conserved regions within any number of sequences in an alignment, searching sequentially through both the forward and reverse complement strands. 35 Putative PU.1 binding sites were scored, based on their positions relative to the transcriptional start sites and their percent identity to the core PU.1 site from the PWM. An overall cut-off similarity of 70% was applied, with a 100% cut-off similarity required for the core PU.1 site. For the current study, sites conserved across mouse and human were included. A nonparametric MannWhitney test was used to analyze the statistical significance of differential representation of PU.1 sites between the groups of genes.
Results
Generation of mice with a second distinct hypomorphic allele of Sfpi1
We previously reported the generation of mice with a hypomorphic allele of the PU.1-encoding gene Sfpi1 termed BN, which expresses B20% of wild-type protein levels. 15 To determine the consequences of removing the PGK promoter and neomycin resistance gene, we performed Cre-mediated excision of loxP elements (described in Materials and methods), thereby generating another allele of Sfpi1 termed Blac (Figure 1a ). Genotypes were confirmed by PCR and Southern blotting (Figure 1b ; data not shown). Sfpi1
Blac/Blac mice were born at near Mendelian frequency (18%, Table 1 ). However, all died within 7 days of birth, as opposed to Sfpi1 BN/BN mice, which survived until weaning, and Sfpi1 À/À mice, which died before birth (Figure 1c ). Colony-forming assays were performed to measure the frequency of fetal liver progenitor cells responsive to granulocyte-colony stimulating factor (G-CSF), macrophage-CSF (M-CSF), GM-CSF or a combination of interleukin-3 (IL-3), IL-6 and stem cell factor (SCF) (Figure 1d ). Sfpi1
Blac/Blac cells generated fewer colonies than Sfpi1 BN/BN cells, which we have previously shown to generate fewer colonies than wild type.
15
Sfpi1
À/À fetal liver cells generated colonies only in IL-3/IL-6/SCF (data not shown).
14 These results show that the Sfpi1 (Figure 1d ; data not shown). Cells of all four genotypes expanded rapidly when switched to liquid cultures containing IL-3. We prepared RNA from cultured cells and performed extensive RT-PCR analysis and sequencing of Sfpi transcripts. We found that the Sfpi1 transcript encoded by the Blac allele was spliced identically to the transcript encoded by the BN allele and also produced PU.1 protein lacking the first 31 amino acids (data not shown). 15 To determine the relative levels of Sfpi1 transcripts, we performed real-time RT-PCR using primers specific to exon 5, which is partially deleted in the Sfpi1 À/À mouse. 3 We validated these primers by analyzing RNA from fetal liver cells cultured in IL-3/ IL-6/SCF for 5 days and verified that PU.1 transcripts were expressed in Sfpi1 BN/BN cells at B20% of wild-type levels (Figure 2a left) . 15 In cells cultured in IL-3 for several weeks, we found that PU.1 transcripts were expressed 7.8-fold lower in Sfpi1
Blac/Blac cells than Sfpi1 BN/BN cells, suggesting that the Blac allele expresses B2% of wild-type levels (Figure 2a right) . PU.1 protein levels from the BN allele were previously shown as 20% of wild type. 15 Immunoblotting with Sfpi1 Blac/Blac lysates could not reproducibly detect PU.1 protein at such low levels ( Figure 2b) ; however, multiple lines of evidence suggest that these cells produce low levels of PU.1 activity (Figures 1c, d and 2e below).
After several passages, wild-type cells grew more slowly than
Blac/Blac cells ( Figure 2c ). Wild-type cell lines were found to be immature mast cells as measured by morphological analysis, high levels of c-Kit and the ability to bind IgE with high affinity (Figure 2d ; data not shown). Previous studies have demonstrated that PU.1 is required for the development of mast cells from fetal liver cells under these culture conditions. 36 Consistently, Sfpi1 À/À cells morphologically resembled immature blasts, expressed intermediate levels of c-Kit, high levels of Gr-1 and FcgRII/III and did not bind IgE (Figure 2d ; data not shown). Unexpectedly, Sfpi1
BN/BN and Sfpi1
Blac/Blac cells also resembled immature blasts and did not Blac/Blac and Sfpi1 À/À mice in the indicated cytokines. Genomic DNA was prepared from E14.5 fetuses, newborns at day 1, mice at day 8 after birth or at the time of weaning at day 21. Genotypes were identified by PCR with primers as shown in Figure 1b .
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bind IgE (Figure 2d ; data not shown 36 Next, we performed RT-PCR analysis for several myeloid genes (Figure 2e ). Microphthalmia-associated transcription factor (Mitf) is critical for mast cell development and has several identified isoforms, one of which is expressed exclusively in mast cells, Mitf-mc. 37 Mitf common was readily detectable in cells of all four genotypes, while mitf-mc was expressed exclusively in wild-type immature mast cells (Figure 2e ). FcgRIIb and FcgRIII are low-affinity receptors for IgG and are expressed in both myeloid and lymphoid cell types (reviewed by Nimmerjahn and Ravetch 38 ). Our laboratory has previously validated FcgRIIb as a PU.1 direct target. 15, 28 Interestingly, FcgRIIb was expressed in a dose-dependent fashion, decreasing from wild type to Sfpi1 BN/BN to Sfpi1 Blac/Blac and absent in Sfpi1 À/À cells, whereas FcgRIII was expressed in cells of all four genotypes (Figure 2e ). This suggests that the cell surface Fcg receptor detected by flow cytometric analysis was FcgRIII (Figure 2d ).
In conclusion, while wild-type cells differentiate into mast
Blac/Blac (Blac) and Sfpi1
(KO) ex vivo cell lines can be utilized as a unique Sfpi1 hypomorphic allelic series in which PU.1 is expressed at B20, B2 or 0% of wild-type levels, respectively. This system can be applied to study the effects of two discrete PU.1 levels on downstream target gene expression.
PU.1 activates and represses groups of target genes at distinct concentrations
To discover how genes respond to distinct levels of PU.1, we performed whole genome microarray analysis to compare gene expression in BN and Blac cell lines with gene expression in the KO cell line (Supplementary Table S2 ). The data was normalized based on Affymetrix internal controls and averaged from three samples of each cell line (described in Materials and methods). As expected, Sfpi1 was expressed in a gradient fashion: 2.25-fold in Blac cells and 7.69-fold in BN cells, (Figure 3a right) .
PU.1 represses T/NK
The patterns shown by the Venn diagrams suggest that genes were regulated by PU.1 in four different modes of either activation or repression (Table 2) . We decided to focus on genes regulated in a gradient manner because dose-dependency suggests that these genes may be direct targets of PU.1 (Figure 3b ). Of the probe sets activated or repressed at both BN and Blac expression levels of PU.1, 76.9% of the activated probe sets and 62.6% of the repressed probe sets were regulated in a gradient fashion (Figure 3a green) . If the definition for gradient regulation was relaxed such that activation in the Blac cells did not have a X2-fold cutoff but was required to be anywhere between BN and KO values, the proportion of genes activated or repressed in a gradient manner increased to 91.9% of the probe sets activated or repressed at both the BN and Blac levels of PU.1. This definition was applied to subsequent analyses of gradient regulated genes.
To identify genes regulated by PU.1 in a gradient fashion, we utilized the web-accessible program Database for Annotation, Visualization and Integrated Discovery 31 to divide our lists into functionally related groups (Figure 3c) . The results show that the two largest groups from both gradient-activated and gradientrepressed lists were receptors and transmembrane proteins and transcription factors, both of which are involved in development and function of the hematopoietic system. Other overlapping groups included kinases, cytolytic proteases, and ion channels, which are involved in general cell homeostasis. Unique groups in the gradient-activated list were protein turnover, also involved in cell homeostasis, and protocadherins, which sense cell-cell interactions and propagate intracellular signaling (reviewed by Halbleib and Nelson 40 ), an important function for immune cells. The Oxygen Transport group was unique to the gradient-repressed list and included many globin genes that are normally expressed in erythroid cells. Globin genes have previously been shown as repressed by PU.1 via interaction with the erythroid transcription factor GATA-1. 26 Overall, the identities of genes activated or repressed by PU.1 in a gradient manner were consistent with known functions of PU.1 in regulating hematopoiesis.
Bioinformatic analysis of predicted PU.1 binding sites
We expected that we could determine if the gradient activated and gradient repressed genes were directly regulated by PU.1 by searching for consensus-binding sites in their promoters. To accomplish this, we compiled known and validated PU.1 target genes (Supplementary Table S3 ) to create a computational PU.1-binding site matrix. With this position weight matrix, we probed the promoters of 549 gradient activated and 400 gradient repressed genes, as well as 580 housekeeping genes as a negative control, and identified conserved putative PU.1 binding sites (described in'Materials and methods). Interestingly, a majority of genes had PU.1 sites that were not conserved between mouse and human and thus were excluded from this analysis (data not shown). An example is transcription factor EC, which has five validated PU.1 binding sites in the mouse gene promoter 41 but none conserved in the human gene promoter. We found that a similar number of genes in all three lists had one predicted PU.1 binding site in their proximal promoters. However, gene promoters from the gradient-activated list had a significantly higher incidence of two or more predicted PU.1 binding sites than gene promoters from either the gradientrepressed list or the housekeeping-control list (Figure 4a ). Next, we identified the positions of all of the predicted PU.1 binding sites in the gradient-regulated lists and grouped them into 100 bp regions (Figure 4b ). The gradient-repressed list had similar numbers of predicted PU.1 binding sites all along the proximal promoter. The gradient-activated list had similar numbers from À1000 to À300 relative to the transcription start site. However, the number of predicted PU.1 sites steadily increased in the most proximal 300 bp. Overall, the gradient activated genes had more predicted PU.1 binding sites in their promoters than the gradient repressed or housekeeping genes, and many were clustered between À300 and the transcription start site. This suggests that activation versus repression of target genes by PU.1 might be mediated by different mechanisms, such as the context of the PU.1 binding sites. It will be important both to determine whether genes are repressed at the transcriptional level and if PU.1 directly interacts with repressed genes.
Gradient repressed genes include T-cell-and natural killer cell-specific genes
It has been established that PU.1 promotes myeloid development. [14] [15] [16] Consistent with this, we found that the largest cluster of genes in the gradient-activated list was myeloid specific and included known PU.1 targets (Table 2; Supplementary Table  S3) . We validated two representative target genes by real-time RT-PCR and confirmed that the genes encoding neutrophil elastase (Ne) and transcription factor EC (Tcfec) were both activated by PU.1 in a gradient fashion (Figure 5a ). Additionally, we were interested in the fact that analysis by DAVID showed 
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that the largest category of genes regulated in a gradient manner by PU.1 included receptors (Figure 3c ). Therefore, we performed a functional validation of the direct PU.1 target GM-CSF receptor-a, Csf2ra. 42 BN cells, but not Blac or KO cells, could be switched to GM-CSF dependence from IL-3 dependence, validating that PU.1 activated the Csf2ra gene significantly in BN cells (Figure 5b ; Table 2 ).
PU.1 represses erythroid development in favor of myeloid development. [24] [25] [26] As expected, we found that one of the two large clusters of genes in the gradient-repressed list was erythroid specific (Table 2) . We validated two representative erythroid genes by real-time RT-PCR and confirmed that the genes encoding the erythropoietin receptor (Epor) and hemoglobin X (Hba-x) were both repressed by PU.1 in a gradient manner. (Figure 5c ). Unexpectedly, the second cluster of gradient repressed genes included T-cell and NK-cell genes (Table 2) . Specifically, these genes were expressed in KO cells and were repressed in a dose-dependent manner by increased PU.1 concentrations in Blac and BN cells. T-cell genes that were repressed in a gradient fashion included CD25 (IL-2Ra, Il2ra) and CD3g (Cd3g). NK-cell genes that were repressed in a gradient manner included CD244 NK-cell receptor 2B4 (Cd244) and the killer cell lectin-like receptors Klra2 and Klrb1d.
We validated representative genes from the T-cell and NK-cell lineages by real-time RT-PCR, and both Cd244 and Il2ra were repressed in a gradient fashion (Figure 5d ). Next, we performed 
PU.1 represses T-cell-and natural killer-cell-specific genes in cultured progenitor B cells
PU.1 is expressed at all stages of B-cell development, but its function after B-cell commitment is not clear. 28, 43, 44 Based on the results described above, we hypothesized that PU.1 might also repress T-cell genes in B cells. Therefore, we re-examined published microarray data from our lab, comparing gene expression in wild type and Sfpi1 À/À pro-B cells. 28 Interestingly, many T-cell-specific genes were highly expressed in Sfpi1 À/À pro-B cells but not in wild-type pro-B cells, including several T-cell receptor transcripts, some of which were also significantly regulated by PU.1 in the IL-3 dependent myeloid cells (Table 2) .
In order to analyze T-cell gene regulation with our system, we generated pro-B cell lines by placing wild-type, Sfpi1
Blac/Blac fetal liver cells into culture with stromal cells and IL-7 (described in Materials and methods). Sfpi1 À/À fetal liver cells do not proliferate under these conditions because they do not express the PU.1 direct target IL-7Ra, as previously described. 36 Wild-type cells generated rapidly proliferating CD19 þ pro-B cell lines within 4 days, while both Sfpi1
and Sfpi1 Blac/Blac cells generated CD19 þ pro-B cell lines in culture with delayed kinetics (Figures 6a and b) . Once generated, Sfpi1 þ / þ (WT), Sfpi1 BN/BN (BN/BN) and Sfpi1
Blac/Blac (Blac/Blac) cell lines grew at similar rates. Surface expression of B220 and FcgRII/III were reduced in a dose-dependent manner in BN/BN and Blac/Blac cells compared to WT cells (Figure 6b) , confirming that PU.1 activates these genes. 28 To determine if T/NK-cell genes were repressed in a gradient manner in response to two distinct hypomophic PU.1 concentrations, we assessed transcription of Zap-70, CD244 and sterile transcripts of the constant regions of the TCRa and -b loci. Analysis by standard and real-time RT-PCR revealed that all four were repressed by PU.1 (Figure 6c) . Next, we validated cellsurface protein expression levels of CD244 with flow cytometry and found that CD244 was expressed in Blac/Blac cells but not in WT or BN/BN cells (Figure 6b) . In summary, several T/NK-cell specific genes were de-repressed in a gradient manner in PU. 1-hypomorphic ex vivo pro-B cell lines. This suggests that PU.1 represses T/NK-cell genes in both the myeloid and B-cell lineages.
Discussion
PU.1 regulates genes involved in hematopoietic cell fate decisions and enforces myeloid and B-cell gene expression programs after lineage commitment. 14, 16, 18 PU.1 is downregulated during early T-cell development, 19, 20 but the biological function of this is not known. In this study, we utilized PU.1 hypomorphic mice and established ex vivo cell lines to examine gene expression in response to three discrete concentrations of PU.1: B20, B2 and 0% of wild-type levels. PU.1 is critical for development of macrophages and neutrophils and has been shown to repress erythroid-specific genes in hematopoietic progenitors and during myelopoiesis. [23] [24] [25] [26] Accordingly, in IL-3 dependent myeloid cell lines, many genes activated or repressed in a dose-dependent manner were, respectively, myeloid or erythroid specific (Table 2 ; Figures 5a and c) . Unexpectedly, T-cell and NK-cell genes were repressed by PU.1 in a dose-dependent manner in both IL-3 dependent myeloid and IL-7 dependent pro-B cells (Table 2 ; Figures 5d, e and 6b, c) . This suggests that PU.1 represses T/NK-cell genes to promote and enforce myeloid and B-cell identity, highlighting that selection of one lineage is concurrent with repression of alternate lineages. Two groups have previously described in vitro systems to examine the effects of PU.1 on gene expression by retrovirally infecting PU.1 cDNA into cytokine-dependent Sfpi1 À/À myeloid progenitor cells. 36, 45 The disadvantages of these approaches are that the levels of PU.1 expression cannot be controlled with precision and that induction of PU.1 results in terminally differentiated myeloid cells. Our hypomorphic allelic system has three major advantages over these approaches. First, changes in gene expression are likely independent of developmental stage, as myeloid differentiation is impaired in BN and Blac cell lines as a consequence of low PU.1 levels (Figures 2d  and e) . Second, BN, Blac and KO cell lines grow at similar rates (Figure 2c ), so gene expression is independent of changes in cell-cycle-related genes. Third, we can measure changes in gene expression in response to two distinct PU.1 concentrations. Therefore, this cell culture system represents a powerful approach to study the effects of changes in PU.1 concentration on gene expression in hematopoietic cells.
The pattern of gene activation and repression observed in response to three distinct PU.1 concentrations (Figure 3a) suggests that PU.1 regulates downstream target genes in four distinct modes ( Figure 7 ; Table 2 ). The 'High Concentrations' mode is comprised of genes activated/repressed by B20% of wildtype levels in BN cells, but not significantly regulated by the B2% level in Blac cells (Figure 3a red) . The 'Low (Figure 3a yellow) . Interestingly, several well-characterized PU.1 target genes, including M-CSFR (Csf1r) and Egr-1 (Egr1), were unaffected in Blac and BN cells (Table 2; Supplementary  Table S3 ). We hypothesize that this is because the level of PU.1 is below a threshold required to activate transcription of these genes.
Our results suggest that an important function of PU.1 in myeloid cells might be to enforce myeloid identity as well as prevent the expression of lineage-inappropriate genes such as erythroid and T/NK-cell genes. It is known that PU.1 directly interacts with GATA-1 at the promoters of erythroid target genes, 23 ,26 but we do not yet know whether T/NK-cell genes are direct or indirect targets of PU.1. Intriguingly, two different laboratories have observed that mice with altered PU.1 expression frequently develop T-cell leukemia. 11, 12 Based on our results, we speculate that inappropriate expression of T-cell genes in response to reduced PU.1 expression might contribute to T-cell leukemia. More work will be needed to identify the molecular mechanism by which PU.1 represses T-cell gene expression in myeloid cells.
PU.1 is expressed throughout B-cell development until it is downregulated upon differentiation into plasma cells. 46 PU.1 is required to generate B-cell progenitors, but its function after B-cell commitment is not well understood, since B cells persist and participate in immune responses after conditional inactivation of the Sfpi1 gene. 43 , 44 Our results demonstrate that T/NKcell genes are transcribed at high levels in cultured pro-B cells with reduced PU.1 expression (Figure 6c) . Thus, we speculate that an important function of PU.1 in B cells might be to repress T/NK-cell genes. Repression of lineage-inappropriate genes, and EBF. 48 Therefore, PU.1 may cooperate with Pax-5 and EBF to repress T-cell genes and enforce B-cell lineage identity. It will be important to identify the degree to which PU.1 overlaps or differs from Pax-5 and EBF in this regard.
It is intriguing that an extremely low level of PU.1, such as that observed in IL-3 dependent myeloid or IL-7 dependent pro-B cells generated from Sfpi1
Blac/Blac fetal liver cells, can potently repress target gene expression. Such low levels of PU.l would be predicted to exist in only one context in vivo, which is during the silencing of PU.1 expression that occurs during erythroid or T-cell differentiation. PU.1 is expressed at the double-negative (DN)1 and DN2 stages of early thymic T-cell development, but is dramatically downregulated upon differentiation into the DN3 stage. 49 Forced expression of PU.1 in pro-T cells efficiently blocks differentiation at the DN3 stage. 22 In addition, PU.1 in combination with the myeloid transcription factor c/EBPa can reprogram T-cell progenitors into myeloid lineage cells. 50 It is clear from these studies that PU.1 plays an important role in regulation of gene expression during early T-cell development, during which, as noted above, it is in the process of being silenced.
In summary, our cell culture system represents an excellent experimental system to investigate the mechanism of how target genes are regulated by PU.1 in a concentration-dependent manner. Taken together, our data suggests that a normal function of PU.1 might be to actively repress T-cell and/or NK-cell gene expression in myeloid and B cells. 
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